Structure Therapeutics (NASDAQ:GPCR) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a sell rating to a hold rating in a research note published on Saturday.

A number of other equities analysts have also recently commented on the company. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 11th. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. HC Wainwright upped their price target on shares of Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a report on Friday, December 19th. Citizens Jmp cut their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday. Finally, BMO Capital Markets restated an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, January 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.50.

Structure Therapeutics Stock Down 2.7%

Shares of NASDAQ:GPCR opened at $62.98 on Friday. The stock has a market cap of $4.45 billion, a PE ratio of -79.72 and a beta of -2.06. The company’s fifty day moving average is $75.41 and its 200 day moving average is $46.73. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Sell-side analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming purchased a new position in shares of Structure Therapeutics during the second quarter valued at about $28,000. EverSource Wealth Advisors LLC boosted its position in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after acquiring an additional 901 shares in the last quarter. CWM LLC grew its holdings in shares of Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares during the period. Assetmark Inc. raised its position in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after acquiring an additional 820 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.